The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
Official Title: A Phase II Study of IL-18 in Melanoma Patients
Study ID: NCT00107718
Brief Summary: This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
GSK Investigational Site, Los Angeles, California, United States
GSK Investigational Site, San Francisco, California, United States
GSK Investigational Site, Santa Monica, California, United States
GSK Investigational Site, New Haven, Connecticut, United States
GSK Investigational Site, Jacksonville, Florida, United States
GSK Investigational Site, Miami Beach, Florida, United States
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Indianapolis, Indiana, United States
GSK Investigational Site, Lutherville-Timonium, Maryland, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, Toledo, Ohio, United States
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
GSK Investigational Site, Waratah, New South Wales, Australia
GSK Investigational Site, Westmead, New South Wales, Australia
GSK Investigational Site, Douglas, Queensland, Australia
GSK Investigational Site, South Brisbane, Queensland, Australia
GSK Investigational Site, Woolloongabba, Queensland, Australia
GSK Investigational Site, Hobart, Tasmania, Australia
GSK Investigational Site, East Melbourne, Victoria, Australia
GSK Investigational Site, Nedlands, Western Australia, Australia
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR